Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi ex­pects its RSV an­ti­body joint­ly de­vel­oped with As­traZeneca will be avail­able next sea­son, ex­ec­u­tive VP of vac­cines Thomas Tri­om­phe an­nounced on the com­pa­ny’s quar­ter­ly call.

Bey­for­tus, al­so known as nir­se­vimab, was ap­proved in the EU back in No­vem­ber and is cur­rent­ly un­der FDA re­view with an ex­pect­ed de­ci­sion com­ing in the third quar­ter of this year. The news comes as the FDA plans to hold ad­vi­so­ry com­mit­tee meet­ings over the next cou­ple months to re­view RSV vac­cines from Pfiz­er and GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER